

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A method for determining a bortezomib therapy regimen for treating a liquid tumor in a patient comprising:
 - a) selecting features from the Predictive Markers in Table 1 to select a predictive marker set;
 - b) determining the level of expression of the features in the predictive marker set; and
 - c) determining a bortezomib regimen for treating the tumor based on the expression of the features in the predictive marker set, wherein a significant expression level is indicative that the patient is either a responsive patient or a non-responsive patient.
2. (Previously Presented) The method of claim 1 wherein the level of expression of the features in the predictive marker set is determined by detection of mRNA.
3. Canceled
4. (Previously Presented) The method of claim 1 wherein the features in the predictive marker set are is selected from at least one of the markers identified in Table 1as having a rank under 100.
5. (Original) The method of claim 1 wherein determining the significant level of expression is determined by comparison with a control marker or by comparison to a predetermined standard.
6. Canceled
7. (Original) The method of claim 1 wherein the liquid tumor is selected from the group consisting of myelomas, multiple myeloma, Non-Hodgkins Lymphoma, B-cell lymphomas, Waldenstrom's syndrome, chronic lymphocytic leukemia, and other leukemias.
8. Canceled

9. Canceled

10. (Original) The method of claim 1, wherein the patient sample comprising tumor cells is obtained from the subject any time selected from prior to tumor therapy, concurrently with tumor therapy or after tumor therapy.

11. – 28. Canceled

29. (Previously Presented) The method of claim 1, wherein the predictive marker set is selected by the Signal-to-Noise Ratio method.

30. (Previously Presented) The method of claim 1, wherein the predictive marker set is selected by the Class-Based Threshold method.

31. (Previously Presented) The method of claim 1, wherein the predictive marker set identifies a responsive patient.

32. (Previously Presented) The method of claim 1, wherein the predictive marker set identifies a non-responsive patient.

33. (Previously Presented) The method of claim 1, wherein the method selects a predictive marker set selected from the group consisting of Table 4, Table 5 and Table 6.

34. – 41. Canceled

42. (New) The method of claim 1, wherein the predictive marker set comprises Predictive Marker No. 149.